Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of int

Application Number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10557534
Filing Date		2005-11-21
First Named Inventor	BLAM	MEY
Art Unit		
Examiner Name		
Attorney Docket Numb	er	RICE-1004US

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	4079199		1978-03-14	PATRONIS, JR.	
	2	4088835		1978-05-09	THURMOND	
	3	4232192		1980-11-04	BEEX	
	4	4449237		1984-05-15	STEPP	
	5	4689618		1987-08-25	AMMITZBOLL	
	6	4845757		1989-07-04	WAGNER	
	7	4905290		1990-02-27	YAOITA	
	8	5016280		1991-05-14	ENGEBRETSON	

### 

	9	5091952		1992-0	2-25	WILLIAMSON					
If you wis	If you wish to add additional U.S. Patent citation information please click the Add button.  Add										
U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date Name of Patentee or Applicant of cited Document		Relev		Lines where ges or Relev			
	1	20040190731		2004-0	9-30	LUO					
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad-	d buttor	n. Add		
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4		Name of Patente Applicant of cited Document	me of Patentee or where Reli		or Relevant	
	1										
If you wish	h to a	dd additional Foreign Pa	itent Do	cument	citation	information pl	ease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Cite Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item Initials* No (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andicer country where published.								Ţ5			
	1									_	
If you wis	h to a	dd additional non-paten	t literatu	ire docui	ment cit	ation informati	on please click the	Add b	utton Ad	d	
				EX	AMINE	R SIGNATUR	E				
Examiner	Signa	ture					Date Conside	ered			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											

	Application Number		10557534	
	Filing Date		2005-11-21	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor BLAN		MEY	
	Art Unit			
	Examiner Name			
	Attorney Docket Numbe	r	RICE-1004US	

See for Codes of USPTO Patient Documents at your USPTO, CODE on MEPP 901.04. \* Exister office in all research on documents, by the loss before code (WPO) Standard 51.3. \* \*Projectioned person of the patient obscurred. The patient obscurred is because the search received the patient obscurred. \* More of document by the appropriate symbols as indicated on the document with the patient obscurred. \* More of document by the appropriate symbols as indicated on the document under WPO Standard 51.56 if possible. \* Applicant is to place a check mark here if Exploit language the search can see a substance of the patient obscurred.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10557534			
Filing Date		2005-11-21			
First Named Inventor BLAN		MEY			
Art Unit					
Examiner Name					
Attorney Docket Numb	er	RICE-1004US			

### CERTIFICATION STATEMENT

Please see	37	CFR :	1 97	and	1.98 to	make	the	appropriate	selection/	s)

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(a)(1).

## ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, not not information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/9/(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/KEVIN J. DUNLEAVY/	Date (YYYY-MM-DD)	2006-05-17
Name/Print	KEVIN I DUNI FAVV	Registration Number	32024

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.